Merit Medical Systems’ chief legal officer sells $3.09m in stock

Brian G. Lloyd, Chief Legal Officer and Secretary of Merit Medical Systems Inc. (NASDAQ:MMSI), recently executed a significant stock transaction. On March 5, 2025, Lloyd sold 30,000 shares of the company’s common stock, generating a total of approximately $3.09 million. The shares were sold at a weighted average price of $102.90, with individual sale prices ranging from $101.92 to $103.36.

In a related transaction on the same day, Lloyd exercised options to acquire 30,000 shares at a price of $55.73 per share. This option exercise, which had a total value of $1.67 million, was part of his compensation package. Following these transactions, Lloyd’s direct ownership stands at 38,945 shares.

In other recent news, Merit Medical Systems reported a strong performance in its fourth quarter of 2024, with earnings per share (EPS) of $0.93, surpassing the forecasted $0.82. The company achieved revenue of $355.2 million, exceeding expectations and reflecting a 9% year-over-year increase. Analysts from Oppenheimer, Needham, and Raymond (NSE:RYMD) James have adjusted their price targets for Merit Medical (TASE:BLWV) to $116, with varying ratings of Outperform and Buy, following the company’s earnings report. Merit Medical’s gross margin saw a notable improvement of approximately 300 basis points year-over-year, marking its highest ever. The company’s free cash flow also showed a significant year-over-year increase of 67%, totaling $185 million for 2024. Looking ahead, Merit Medical has provided guidance for 2025, projecting organic revenue growth of 5.5-6.5% and non-GAAP EPS in the range of $3.58 to $3.70. The company’s recent acquisitions, including Cook Medical and EndoGastric Solutions, have been highlighted as performing beyond initial expectations. Merit Medical’s new product, WRAPSODY, is expected to contribute to the company’s growth as training programs expand and reimbursement visibility improves.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.